---
title: "Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: References"
description: "Reference list for the formulary evidence report on Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis. 85 cited documents."
canonical: "https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: References

<a id="references"></a>

## 5 References

1. [Akasaka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26264717/)
2. [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/)
3. [Ataya et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39947303/)
4. [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf)
5. [Bonella and Borie (2025a)](https://pubmed.ncbi.nlm.nih.gov/41110926/)
6. [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)
7. [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)
8. [Bonella et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2902941-1/fulltext)
9. [Campo et al. (2022)](https://www.nature.com/articles/s41598-022-11446-8)
10. [Campo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10764982/)
11. [Carey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026347/)
12. [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap)
13. [Chen et al. (2025a)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1552566/full)
14. [Chen et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40529121/)
15. [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf)
16. [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)
17. [ClinicalTrials.gov NCT04544293 statistical analysis plan](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/SAP_001.pdf)
18. [ClinicalTrials.gov NCT06431776](https://clinicaltrials.gov/study/NCT06431776)
19. [ClinicalTrials.gov NCT06546098](https://clinicaltrials.gov/study/NCT06546098)
20. [CTIS.eu 2024-512039-66-00](https://ctis.eu/trial/2024-512039-66-00)
21. [Dang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42045620/)
22. [European Respiratory Society](https://publications.ersnet.org/content/erj/64/5/2400725)
23. [FDA Orphan Drug Designations and Approvals (2012)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=377912)
24. [Futami et al. (2026)](https://www.nature.com/articles/s41467-026-74717-2)
25. [Gajewska et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5925949/)
26. [Guirriec et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11610044/)
27. [Higgins et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42466621/)
28. [Inoue et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2720118/)
29. [Inoue et al. (2026)](https://savarapharma.com/wp-content/uploads/Inoue-Biomarker-ERS-2026-Poster.pdf)
30. [Jehn and Bonella (2023)](https://pubmed.ncbi.nlm.nih.gov/37395514/)
31. [Jouneau et al. (2025)](https://link.springer.com/article/10.1007/s40265-025-02228-3)
32. [Kavuru et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21478218/)
33. [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9509629/)
34. [Kim et al. (2024)](https://savarapharma.com/wp-content/uploads/Poster-1.pdf)
35. [Lee et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03478-2)
36. [Lettieri et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39142709/)
37. [Loyola Medicine](https://www.loyolamedicine.org/clinical-research/clinical-trials/NCT04544293)
38. [Luisetti et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20728558/)
39. [Mabo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37758458/)
40. [McCarthy (2025b)](https://savarapharma.com/wp-content/uploads/Efficacy-of-Inhaled-Molgramostim-According-to-Severity-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-aPAP.pdf)
41. [McCarthy et al. (2018)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0846-y)
42. [McCarthy et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9851473/)
43. [McCarthy et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12582097/)
44. [McCarthy et al. (2026a)](https://publications.ersnet.org/content/errev/35/180/250237)
45. [McCarthy et al. (2026b)](https://savarapharma.com/wp-content/uploads/McCarthy-EC-ERS-2026-Poster.pdf)
46. [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)
47. [Munsif et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10663936/)
48. [Naeem et al. (2026)](https://link.springer.com/article/10.1186/s12890-026-04179-1)
49. [Narita et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12865520/)
50. [National Health Care Institute Horizonscan Geneesmiddelen (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/molgramostim?versie=versie-7)
51. [Papiris et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24890235/)
52. [Savara Inc. (2024)](https://investors.savarapharma.com/news/news-details/2024/Savara-Announces-Expanded-Access-Program-EAP-for-Molgramostim-Inhalation-Solution-Molgramostim-for-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-aPAP-09-27-2024/default.aspx)
53. [Savara Inc. autoimmune PAP clinical trials page](https://savarapharma.com/our-science/what-is-apap/clinical-trials-in-apap/)
54. [Savara Inc. autoimmune PAP disease page](https://savarapharma.com/our-science/what-is-apap/)
55. [Savara Inc. BLA refusal to file announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/Savara-Receives-Refusal-to-File-RTF-Letter-From-the-U-S--Food-and-Drug-Administration-FDA-for-the-Biologics-License-Application-BLA-for-MOLBREEVI-to-Treat-Patients-With-Autoimmune-Pulmonary-Alveolar-Proteinosis-autoimmune-PAP/default.aspx)
56. [Savara Inc. BLA resubmission announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/Savara-Resubmits-the-Biologics-License-Application-BLA-to-the-U-S--Food-and-Drug-Administration-FDA-for-MOLBREEVI-for-the-Potential-Treatment-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)
57. [Savara Inc. BLA review extension announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-the-U-S--Food--Drug-Administration-FDA-Has-Extended-the-Review-Period-for-the-Molgramostim-Inhalation-Solution-Molgramostim-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)
58. [Savara Inc. ERS 2026 encore presentations announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-Encore-Presentations-of-Results-from-the-Phase-3-Clinical-Trial-of-Molgramostim-Inhalation-Solution-Molgramostim-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-APAP-at-the-European-Respiratory-Society-ERS-Congress-2026/default.aspx)
59. [Savara Inc. ERS presentation (2019)](https://savarapharma.com/wp-content/themes/savara/pdf/20191008_IMPALA-ERS-FINAL-REV.pdf)
60. [Savara Inc. expanded access policy](https://savarapharma.com/development/expanded-access-policy/)
61. [Savara Inc. Form 10-K (2023)](https://www.sec.gov/Archives/edgar/data/1160308/000095017023010967/svra-20221231.htm)
62. [Savara Inc. Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1160308/000119312526344585/svra-20260630.htm)
63. [Savara Inc. health claims analysis announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/Savara-Announces-New-U-S--Health-Claims-Data-Analysis-Finds-Over-50-Increase-in-the-Estimated-Number-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP-Patients-Compared-to-Previous-Claims-Analysis/default.aspx)
64. [Savara Inc. investor relations home page](https://investors.savarapharma.com/)
65. [Savara Inc. MOLBREEVI in autoimmune PAP page](https://savarapharma.com/our-science/what-is-apap/clinical-trials-in-apap/molbreevi-in-apap/)
66. [Savara Inc. MOLBREEVI regulatory update announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Provides-Regulatory-Update-on-the-MOLBREEVI-Development-Program-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)
67. [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)
68. [Savara Inc. PANTHERx Rare specialty pharmacy announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/PANTHERx-Rare-Selected-by-Savara-as-the-U-S--Exclusive-Specialty-Pharmacy-for-MOLBREEVI/default.aspx)
69. [Savara Inc. second quarter 2026 results announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx)
70. [Sheng et al. (2018)](https://link.springer.com/article/10.1186/s12931-018-0862-4)
71. [Soyez et al. (2018)](https://link.springer.com/article/10.1186/s12931-018-0780-5)
72. [Strong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12174958/)
73. [Tazawa et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31483963/)
74. [Tian et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330972/)
75. [Trapnell (2024a)](https://savarapharma.com/wp-content/uploads/Trapnell-IMPALA-PLS-Hospital-Practice-2024.pdf)
76. [Trapnell and Chowdhury (2022)](https://savarapharma.com/wp-content/uploads/impala-2.pdf)
77. [Trapnell et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30846703/)
78. [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)
79. [Trapnell et al. (2024b)](https://savarapharma.com/wp-content/uploads/IMPALA-2-ERS-2024-Poster-FINAL.pdf)
80. [Trapnell et al. (2025a)](https://doi.org/10.1056/nejmoa2410542)
81. [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)
82. [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)
83. [Wang et al. (2025)](https://savarapharma.com/wp-content/uploads/Wang-GGO-WLL-ATS-2025-Poster-FINAL.pdf)
84. [WHO Collaborating Centre for Drug Statistics Methodology (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L03AA03)
85. [Xiong et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12871052/)

## Related pages
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations.md)
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Economic information and modeling report](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: prevalence by geography](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses.md)
